Nature Communications (Dec 2016)
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence
- Ajinkya Revandkar,
- Maria Luna Perciato,
- Alberto Toso,
- Abdullah Alajati,
- Jingjing Chen,
- Hermeto Gerber,
- Mitko Dimitrov,
- Andrea Rinaldi,
- Nicolas Delaleu,
- Emiliano Pasquini,
- Rocco D’Antuono,
- Sandra Pinton,
- Marco Losa,
- Letizia Gnetti,
- Alberto Arribas,
- Patrick Fraering,
- Francesco Bertoni,
- Alain Nepveu,
- Andrea Alimonti
Affiliations
- Ajinkya Revandkar
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Maria Luna Perciato
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Alberto Toso
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Abdullah Alajati
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Jingjing Chen
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Hermeto Gerber
- Brain Mind Institute and School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL)
- Mitko Dimitrov
- Brain Mind Institute and School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL)
- Andrea Rinaldi
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Nicolas Delaleu
- Department of Clinical Science, Broegelmann Research Laboratory, University of Bergen
- Emiliano Pasquini
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Rocco D’Antuono
- Institute for Research in Biomedicine, University of Italian Switzerland, Via Vincenzo Vela 6, Bellinzona 6500, Switzerland
- Sandra Pinton
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Marco Losa
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Letizia Gnetti
- Pathology Unit, University Hospital of Parma
- Alberto Arribas
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Patrick Fraering
- Brain Mind Institute and School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL)
- Francesco Bertoni
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- Alain Nepveu
- Department of Oncology, Rosalind and Morris Goodman Cancer Research Center, Biochemistry and Medicine, McGill University
- Andrea Alimonti
- Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
- DOI
- https://doi.org/10.1038/ncomms13719
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 12
Abstract
Notch signalling is involved in prostate cancer progression and therapeutic resistance. Here, the authors show that loss of PTEN in prostate cancer models results in increased Notch1 cleavage and activation through CUX1-mediated transactivation of ADAM17.
